Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AB0024 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AB0024 | EXPERIMENTAL | The starting dose for Part A will be 1 mg/kg. Subsequent doses of 3, 10, and 20 mg/kg are planned. Three to 6 patients will be enrolled using a 3 + 3 design. Doses of AB0024 will be administered on Days 1, 15, 29, and 43 to characterize the safety, tolerability, and PK. The dose expansion phase of the study will begin upon completion of the dose escalation phase. Up to 20 patients will be enrolled into one or two cohorts of Part B. The first expansion cohort will be dosed up to the MTD defined as the highest dose level with an observed incidence of DLT in \<33% of patients enrolled from Part A. |
| Name | Type | Description |
|---|---|---|
| AB0024 | DRUG | Comparison of different dosages of drug |
Inclusion Criteria: * Histologically or cytologically confirmed advanced malignant solid tumor that is refractory to, intolerant of, or for which no standard of therapy is available * Measurable or evaluable disease * ECOG Performance Status of ≤2 * No known active central nervous system (CNS) tumo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
AB0024 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed by Gilead Sciences, Inc. for use in oncology, specifically in adults with advanced solid tumors.
AB0024 is being developed by Gilead Sciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol GILD. The company is conducting clinical research to evaluate the safety and tolerability of this investigational small molecule in patients with advanced solid tumors.
AB0024 is in Phase 1 clinical development. It has completed a first-in-human study that evaluated its safety and tolerability in adults with advanced solid tumors. As an investigational drug, it is not yet approved by regulatory authorities and remains in clinical development.
AB0024 has been studied in one clinical trial, identified as NCT01323933, titled 'First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors.' This Phase 1 study was completed in the United States and enrolled 32 participants with neoplasms.
AB0024 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it has not received marketing approval from the U.S. Food and Drug Administration or any other regulatory agency. Its safety and efficacy have not been established for any indication.